# Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Clinical trial · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

- Archive id: nct:NCT07307053
- Published: 2025-12-29
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07307053
- Source URL: https://clinicaltrials.gov/study/NCT07307053
- Provenance: clinicaltrials

## Abstract

The goal of this Phase I/II observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors. The study utilizes multi-dimensional precision screening (including WES, RNAseq, mIHC, and quantitative proteomics) to match patients with specific sub-protocols. Key questions it aims to answer: Assess the safety of innovative therapies in rare tumor populations. Evaluate the objective response rate (ORR) and other efficacy metrics. Explore biomarkers related to therapeutic efficacy. Participants: Patients with metastatic or advanced rare solid tumors who have failed standard therapy or have no standard treatment options.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: NOT_YET_RECRUITING
- phase: PHASE1, PHASE2
- study type: INTERVENTIONAL
- enrollment: 600
- sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- conditions: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
- interventions: DRUG: BL-B01D1; DRUG: VSV injection; DRUG: CVL006; BIOLOGICAL: IDOV-SAFE; BIOLOGICAL: KXV01 TCR Lentinvivo Injection; BIOLOGICAL: MT027; BIOLOGICAL: QH101; BIOLOGICAL: Meta10-TIL; BIOLOGICAL: TAEST1901; BIOLOGICAL: TC-N201
- start date: 2026-01-01
- start date type: ESTIMATED
- primary completion date: 2029-01-31
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [mRNA Therapeutics & Cancer Vaccines](https://space-kitty.com/topics/mrna-cancer-vaccines)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.